ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
bearish•InnoCare Pharma
•20 Mar 2020 12:21

InnoCare (诺诚健华) IPO Trading: At the Mercy of Retail Flipping

InnoCare, a China-based biotech company founded by a famous scientist, raised USD 270 million at HKD 8.95 per share. In this insight, we will cover...

Logo
628 Views
Share
bullish•Peijia Medical
•18 Feb 2020 10:34

Peijia Medical (沛嘉医疗) Pre-IPO: Reminiscence of Venus Medtech?

Peijia Medical is a leading domestic player in the transcatheter valve therapeutic medical device market and the neurointerventional procedural...

Logo
1.4k Views
Share
bullish•Alibaba
•16 Jan 2020 14:57

2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
723 Views
Share
•14 Jan 2020 17:44

Jiumaojiu (九毛九) Trading - Off to a Great Start with 638x Oversubscription

Jiumaojiu (9922 HK) raised about US$283m at HK$6.60 per share, the top end of its IPO price range. We have previously covered the IPO...

Share
•09 Dec 2019 17:08

Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level

Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...

Logo
711 Views
Share
x